Coherus BioSciences, Inc. (CHRS)
| Market Cap | 580.67M |
| Revenue (ttm) | 303.63M |
| Net Income (ttm) | -210.24M |
| Shares Out | 77.42M |
| EPS (ttm) | -2.75 |
| PE Ratio | n/a |
| Forward PE | 32.89 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,680,376 |
| Open | 7.48 |
| Previous Close | 7.39 |
| Day's Range | 7.22 - 7.66 |
| 52-Week Range | 5.60 - 19.32 |
| Beta | 1.21 |
| Analysts | Buy |
| Price Target | 19.96 (+166.1%) |
| Earnings Date | Aug 4, 2022 |
About CHRS
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma in China; Bevacizumab biosimilar; and CHS-1420, an anti-TNF product candidate, as an adalimumab bios... [Read more...]
Financial Performance
Financial StatementsAnalyst Forecast
According to 13 analysts, the average rating for CHRS stock is "Buy." The 12-month stock price forecast is 19.96, which is an increase of 166.13% from the latest price.
News
Coherus BioSciences Announces New Employment Inducement Grants
REDWOOD CITY, Calif., June 22, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective June 16, 2022, the compensation committee of ...
Coherus BioSciences Appoints Dr. Jill O'Donnell-Tormey to its Board of Directors
- Dr. O'Donnell-Tormey is a cancer immunology key opinion leader with more than 30 years leading the Cancer Research Institute's efforts to advance cancer immunotherapies -
Coherus BioSciences Management to Present at Upcoming Investor Conferences
REDWOOD CITY, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), announced today that senior management will present at the following investor conferences in May.
Coherus BioSciences (CHRS) Reports Q1 Loss, Misses Revenue Estimates
Coherus BioSciences (CHRS) delivered earnings and revenue surprises of -55% and 11.68%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Coherus BioSciences Reports First Quarter 2022 Results
– CIMERLI ™ BLA review progressing toward August 2022 action date – – Toripalimab BLA resubmission expected by mid-summer – – UDENYCA® delivers 1 st quarter 2022 net sales of $60.1 million – – 2022 R&D ...
Coherus BioSciences Appoints Charlie Newton to Board of Directors
- Biotechnology Chief Financial Officer and highly regarded former healthcare investment banker brings decades of industry experience to Coherus' immuno-oncology strategy execution -
FDA Rejects Junshi - Coherus' Toripalimab For Rare Head & Neck Cancer
The FDA has issued a complete response letter (CRL) to Junshi Biosciences Co Ltd and Coherus BioSciences Inc's (NASDAQ: CHRS) toripalimab application for advanced recurrent or metastatic nasopharyngeal ...
CORRECTION - Coherus BioSciences to Report First Quarter 2022 Financial Results on May 5th, 2022
REDWOOD CITY, Calif., April 29, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Coherus BioSciences, Inc. (Nasdaq: CHRS), please note in the Conference Call Informa...
Coherus BioSciences to Report First Quarter 2022 Financial Results on May 5th, 2022
REDWOOD CITY, Calif., April 29, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its first quarter 2022 financial results will be released after the clo...
Coherus BioSciences (CHRS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Coherus BioSciences (CHRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Coherus Highlights Anticipated New Product Launches and Immuno-oncology Growth Strategy at Analyst Day Event
— Multiple near-term anticipated product launches and development of innovative immuno-oncology pipeline position Coherus for long-term growth –
Coherus BioSciences to Highlight New Product Pipeline, Cancer Immunotherapy Development Plans at March 29, 2022 Analy...
REDWOOD CITY, Calif., March 22, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that Coherus plans to host an Analyst Day on March 29, 2022 at 9:30 a.m. ET ...
Coherus BioSciences Appoints Rosh Dias, MD, MRCP, Chief Medical Officer
- Dr. Dias is a biotech and pharma industry executive with more than 20 years of global experience launching oncology products - - Dr. Dias is a biotech and pharma industry executive with more than 20 y...
Coherus Management to Present at Upcoming Investor Conferences
REDWOOD CITY, Calif., March 04, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at the following investor conferences in...
Coherus BioSciences' Q4 Sales Fall 34% On Lower Udenyca Volume, Prices
Coherus BioSciences Inc's (NASDAQ: CHRS) Q4 net revenue was $73.4 million for Q4 FY21 compared to $110.4 million for the same period in 2020, missing estimates of $85.81 million. The decline was primari...
Coherus BioSciences (CHRS) Reports Q4 Loss, Misses Revenue Estimates
Coherus BioSciences (CHRS) delivered earnings and revenue surprises of 1.64% and 11.94%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Coherus BioSciences Reports Fourth Quarter and Full Year 2021 Results
– YUSIMRY™ (adalimumab-aqvh), Coherus' second product, approved by FDA on December 17, 2021 – – BLAs under FDA review for PD-1 inhibitor toripalimab and CIMERLI™ (ranibizumab-ranq) – – New FDA filings e...
Coherus Names Paul Reider Chief Commercial Officer
REDWOOD CITY, Calif., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: “CHRS”, “the Company”, “Coherus”) today announced Paul Reider has been named Chief Commercial Officer. Mr. Reid...
Coherus BioSciences to Report Fourth Quarter and Full Year 2021 Financial Results on February 17th, 2022
REDWOOD CITY, Calif., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its fourth quarter and full year 2021 financial results will be released...
Coherus BioSciences Appoints Health Care Payer Expert Lee N. Newcomer, M.D.
Jim Healy, Director since 2014, steps down from the Coherus board Jim Healy, Director since 2014, steps down from the Coherus board
Coherus BioSciences Secures Credit Financing with Pharmakon Advisors
Balance sheet strengthened to support commercial launches of as many as five new products in 2022 and 2023 Balance sheet strengthened to support commercial launches of as many as five new products in 20...
Coherus BioSciences Management to Present at the 40th Annual J.P. Morgan Healthcare Conference
REDWOOD CITY, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at the virtual 40th Annual J.P. Morgan He...
Coherus Announces U.S. FDA Approval of YUSIMRY™ (adalimumab-aqvh)
- Approved for all eligible indications of the reference biological product, Humira® (adalimumab) -
Coherus BioSciences Appoints Theresa LaVallee, Ph.D., Chief Development Officer
REDWOOD CITY, Calif., Dec. 17, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced the addition of Theresa LaVallee, Ph.D. as its Chief Development Officer. Dr. LaVallee w...